Year Published
- (-) Remove 2008 filter 2008
- 2009 (1) Apply 2009 filter
- 2010 (1) Apply 2010 filter
- 2011 (1) Apply 2011 filter
- 2012 (0)
- 2013 (0)
- 2014 (0)
- 2015 (0)
- 2016 (3) Apply 2016 filter
- (-) Remove 2017 filter 2017
- 2018 (1) Apply 2018 filter
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (1) Apply Smallholder Farmers filter
- Women (1) Apply Women filter
Types of Research
- Data Analysis (1) Apply Data Analysis filter
- Literature Review (2) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- East Africa Region and Selected Countries (2) Apply East Africa Region and Selected Countries filter
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (0)
- Southern Africa Region and Selected Countries (0)
- (-) Remove Sub-Saharan Africa filter Sub-Saharan Africa
- West Africa Region and Selected Countries (0)
Dataset
- ASTI (1) Apply ASTI filter
- FAOSTAT (1) Apply FAOSTAT filter
- Farmer First (0)
- LSMS & LSMS-ISA (1) Apply LSMS & LSMS-ISA filter
- Other Datasets (0)
Current search
- (-) Remove Household Well-Being & Equity filter Household Well-Being & Equity
- (-) Remove Sub-Saharan Africa filter Sub-Saharan Africa
- (-) Remove Global filter Global
- (-) Remove 2017 filter 2017
- (-) Remove Technology filter Technology
- (-) Remove Risk, Preferences, & Decision-Making filter Risk, Preferences, & Decision-Making
- (-) Remove 2008 filter 2008
- (-) Remove Research & Development filter Research & Development
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
A growing body of evidence suggests that empowering women may lead to economic benefits (The World Bank, 2011; Duflo, 2012; Kabeer & Natali, 2013). Little work, however, focuses specifically on the potential impacts of women’s empowerment in agricultural settings. Through a comprehensive review of literature this report considers how prioritizing women’s empowerment in agriculture might lead to economic benefits. With an intentionally narrow focus on economic empowerment, we draw on the Women’s Empowerment in Agriculture Index (WEAI)’s indicators of women’s empowerment in agriculture to consider the potential economic rewards to increasing women’s control over agricultural productive resources (including their own time and labor), over agricultural production decisions, and over agricultural income. While we recognize that there may be quantifiable benefits of improving women’s empowerment in and of itself, we focus on potential longer-term economic benefits of improvements in these empowerment measures.